Kathleen N Moore1, Michael W Sill2, Meaghan E Tenney3, Christopher J Darus4, David Griffin5, Theresa L Werner6, Peter G Rose7, Robert Behrens8. 1. Stephenson Oklahoma Cancer Center, 800 NE 10th Street, Oklahoma City, OK 73104, United States. Electronic address: Kathleen-Moore@ouhsc.edu. 2. NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States. Electronic address: msill@gogstats.org. 3. University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, United States. Electronic address: mtenney@babies.bsd.uchicago.edu. 4. Maine Medical Center, 102 Campus Drive Unit 116, Scarborough, ME 04074, United States. Electronic address: darusc@mmc.org. 5. Upstate Carolina CCOP Oncology Research, 101 East Wood Street, Spartanburg, SC 29303, United States. Electronic address: david_griffin@bshsi.org. 6. Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, United States. Electronic address: theresa.werner@hci.utah.edu. 7. Cleveland Clinic Foundation, 9500 Euclid Avenue, A81, Cleveland, OH 44106, United States. Electronic address: rosep@ccf.org. 8. Cancer Center of Iowa, Iowa Wide Oncology Research Coalition, 1221 Pleasant Street, Suite 450, Des Moines IA 50309, United States. Electronic address: rbehrens@cancercenterofiowa.com.
Abstract
OBJECTIVES: Ang1 & 2 (angiopoietin-1; -2) interact with Tie2 receptors on endothelial cells to mediate vascular remodeling in an angiogenesis signaling pathway distinct from the VEGF axis. Trebananib is a peptide Fc fusion protein that binds Ang1 and 2 and prevents interaction with Tie2. The efficacy of trebananib in recurrent/persistent endometrial cancer (EC) was studied. METHODS: The primary objective was to determine the frequency of patients with objective tumor responses (ORR) and event-free survival for ≥6months (6-month EFS) and determine toxicity of trebananib at a dose and schedule of 15mg/kg, IV QW. Recurrent/persistent EC, measurable disease, and ≤2 prior chemotherapy lines were required. RESULTS: Thirty-two patients were eligible and treated. The most common histologies were G1/2 endometrioid (31%), G3 endometrioid (28%) and serous (31.3%). 78% of patients had 1 prior regimen. Patients received 1-9+ cycles of trebananib; 24 patients (75%) received ≤2cycles. One patient had a partial response (3.1%); 8 patients had stable disease (25%) and 5 patients (15.6%) had 6 month EFS. Median progression-free survival and overall-survival were 1.97 months (90% CI 1.77-2.1) and 6.6 months (90% CI 4.01-14.75), respectively. Most common adverse events (AEs) were fatigue, anemia, and GI issues. Grade 3 and 4 AEs were: GI 31 and 0%; vascular 22 and 0%; metabolism/nutrition 19 and 3%; and general (including edema) 16 and 0%. CONCLUSIONS: Trebananib has insufficient single agent activity in recurrent EC to warrant further investigation at this dose/schedule.
OBJECTIVES:Ang1 & 2 (angiopoietin-1; -2) interact with Tie2 receptors on endothelial cells to mediate vascular remodeling in an angiogenesis signaling pathway distinct from the VEGF axis. Trebananib is a peptide Fc fusion protein that binds Ang1 and 2 and prevents interaction with Tie2. The efficacy of trebananib in recurrent/persistent endometrial cancer (EC) was studied. METHODS: The primary objective was to determine the frequency of patients with objective tumor responses (ORR) and event-free survival for ≥6months (6-month EFS) and determine toxicity of trebananib at a dose and schedule of 15mg/kg, IV QW. Recurrent/persistent EC, measurable disease, and ≤2 prior chemotherapy lines were required. RESULTS: Thirty-two patients were eligible and treated. The most common histologies were G1/2 endometrioid (31%), G3 endometrioid (28%) and serous (31.3%). 78% of patients had 1 prior regimen. Patients received 1-9+ cycles of trebananib; 24 patients (75%) received ≤2cycles. One patient had a partial response (3.1%); 8 patients had stable disease (25%) and 5 patients (15.6%) had 6 month EFS. Median progression-free survival and overall-survival were 1.97 months (90% CI 1.77-2.1) and 6.6 months (90% CI 4.01-14.75), respectively. Most common adverse events (AEs) were fatigue, anemia, and GI issues. Grade 3 and 4 AEs were: GI 31 and 0%; vascular 22 and 0%; metabolism/nutrition 19 and 3%; and general (including edema) 16 and 0%. CONCLUSIONS: Trebananib has insufficient single agent activity in recurrent EC to warrant further investigation at this dose/schedule.
Authors: Bradley J Monk; Andrés Poveda; Ignace Vergote; Francesco Raspagliesi; Keiichi Fujiwara; Duk-Soo Bae; Ana Oaknin; Isabelle Ray-Coquard; Diane M Provencher; Beth Y Karlan; Catherine Lhommé; Gary Richardson; Dolores Gallardo Rincón; Robert L Coleman; Thomas J Herzog; Christian Marth; Arija Brize; Michel Fabbro; Andrés Redondo; Aristotelis Bamias; Marjan Tassoudji; Lynn Navale; Douglas J Warner; Amit M Oza Journal: Lancet Oncol Date: 2014-06-17 Impact factor: 41.316
Authors: Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle Journal: Gynecol Oncol Date: 2013-02-21 Impact factor: 5.482
Authors: Don S Dizon; Michael W Sill; Jeanne M Schilder; Kathryn F McGonigle; Zia Rahman; David S Miller; David G Mutch; Kimberly K Leslie Journal: Gynecol Oncol Date: 2014-10-13 Impact factor: 5.482
Authors: D Scott McMeekin; Michael W Sill; Doris Benbrook; Kathleen M Darcy; Deborah J Stearns-Kurosawa; Lynne Eaton; S Diane Yamada Journal: Gynecol Oncol Date: 2007-02-15 Impact factor: 5.482
Authors: Matthew A Powell; Michael W Sill; Paul J Goodfellow; Doris M Benbrook; Heather A Lankes; Kimberly K Leslie; Yvette Jeske; Robert S Mannel; Monique A Spillman; Paula S Lee; James S Hoffman; D Scott McMeekin; Pamela M Pollock Journal: Gynecol Oncol Date: 2014-07-11 Impact factor: 5.482
Authors: Howard D Homesley; Nathan P Meltzer; Lucybeth Nieves; Luis Vaccarello; George S Lowendowski; Al A Elbendary Journal: Int J Clin Oncol Date: 2008-02-29 Impact factor: 3.402
Authors: Vincent Castonguay; Stephanie Lheureux; Stephen Welch; Helen J Mackay; Hal Hirte; Gini Fleming; R Morgan; Lisa Wang; Chantale Blattler; Percy S Ivy; Amit M Oza Journal: Gynecol Oncol Date: 2014-05-29 Impact factor: 5.482
Authors: Vicky Makker; Virginia L Filiaci; Lee-May Chen; Christopher J Darus; James E Kendrick; Gregory Sutton; Katherine Moxley; Carol Aghajanian Journal: Gynecol Oncol Date: 2015-04-16 Impact factor: 5.482
Authors: Marie Viala; Marie Vinches; Marie Alexandre; Caroline Mollevi; Anna Durigova; Nadia Hayaoui; Krisztian Homicsko; Alice Cuenant; Céline Gongora; Luca Gianni; Diego Tosi Journal: Br J Cancer Date: 2018-02-13 Impact factor: 7.640
Authors: Vicky Makker; Angela K Green; Robert M Wenham; David Mutch; Brittany Davidson; David Scott Miller Journal: Gynecol Oncol Res Pract Date: 2017-12-02
Authors: Roberto Carmagnani Pestana; Manal M Hassan; Reham Abdel-Wahab; Yehia I Abugabal; Lauren M Girard; Donghui Li; Ping Chang; Kanwal Raghav; Jeff Morris; Robert A Wolff; Asif Rashid; Hesham M Amin; Ahmed Kaseb Journal: Oncotarget Date: 2018-12-28
Authors: Heidi Rütten; Cornelia Verhoef; Willem Jan van Weelden; Anke Smits; Joëlle Dhanis; Nelleke Ottevanger; Johanna M A Pijnenborg Journal: Cancers (Basel) Date: 2021-12-14 Impact factor: 6.639